189 related articles for article (PubMed ID: 10779792)
21. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
23. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces.
Washburn RG; Bryant-Varela BJ; Julian NC; Bennett JE
Mol Immunol; 1991; 28(4-5):465-70. PubMed ID: 2062324
[TBL] [Abstract][Full Text] [Related]
24. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
25. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.
Gates MA; Kozel TR
Infect Immun; 2006 Jun; 74(6):3096-106. PubMed ID: 16714537
[TBL] [Abstract][Full Text] [Related]
26. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
27. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
Feldmesser M; Casadevall A
Front Biosci; 1998 Feb; 3():d136-51. PubMed ID: 9445465
[TBL] [Abstract][Full Text] [Related]
29. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
Mukherjee J; Nussbaum G; Scharff MD; Casadevall A
J Exp Med; 1995 Jan; 181(1):405-9. PubMed ID: 7807020
[TBL] [Abstract][Full Text] [Related]
30. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
31. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.
Belay T; Cherniak R; Kozel TR; Casadevall A
Infect Immun; 1997 Feb; 65(2):718-28. PubMed ID: 9009335
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
Percival A; Thorkildson P; Kozel TR
Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
[TBL] [Abstract][Full Text] [Related]
34. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
Young BJ; Kozel TR
Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
[TBL] [Abstract][Full Text] [Related]
35. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
[TBL] [Abstract][Full Text] [Related]
36. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.
McClelland EE; Casadevall A
Fungal Genet Biol; 2012 Mar; 49(3):227-34. PubMed ID: 22327012
[TBL] [Abstract][Full Text] [Related]
37. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
Casadevall A; Scharff MD
J Exp Med; 1991 Jul; 174(1):151-60. PubMed ID: 1676047
[TBL] [Abstract][Full Text] [Related]
38. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
39. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.
Cleare W; Casadevall A
Clin Diagn Lab Immunol; 1998 Mar; 5(2):125-9. PubMed ID: 9521132
[TBL] [Abstract][Full Text] [Related]
40. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen.
McLean GR; Torres M; Elguezabal N; Nakouzi A; Casadevall A
J Immunol; 2002 Aug; 169(3):1379-86. PubMed ID: 12133962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
